Veritas Pharma Proceeds Towards Clincial Trials



July 10, 2017 / TheNewswire / Vancouver, B.C. –
Veritas Pharma Inc. (CSE: VRT; OTC: VRTHF; and Frankfurt: 2VP), an emerging discovery and IP development company, is pleased to
announce that its research arm, Cannevert Therapeutics Ltd. (CTL) will be sending a team overseas next week to assess more
medicinal cannabis licensed producers as well as clinical research organizations to determine their potential as sources of
cannabis material and clinical trial sites, respectively.  Cannevert’s aim is to investigate more of its lead analgesic
extracts later this year.


Veritas CEO, Dr. Lui Franciosi commented, ‘As we continue to explore Europe for possible clinical
trial sites (previously indicating The Netherlands), which are confounded by cost and legal restrictions, Veritas and Cannevert
have been looking at other continents.  Our latest potential site is in a special part of the United States, Puerto Rico,
which because of their extensive

... read more at:

Leave a Reply

Your email address will not be published. Required fields are marked *